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A recent consensus document based on a metaanalysis of published studies recommends that OPCAB should be considered in both low-risk and high-risk patients to reduce perioperative mortality, morbidity, and resource utilization beyond that achieved with CPB surgery. 1 This analysis suggested that OPCAB potentially decreases perioperative myocardial infarction and other myocardial injury, stroke, atrial fibrillation, renal damage, and injury to the brain. Another study reported that OPCAB patients have decreased atrial fibrillation, transfusion and inotrope requirements, respiratory infections, ventilation time, ICU stay, and hospital stay. 2 However, several meta-analyses showed that there is no difference (advantage) in short-term or long-term mortality and morbidity between OPCAB and on-pump cardiopulmonary bypass-coronary artery bypass grafting (CPB-CABG) as shown in observational studies. 1, 3, 4 Moreover, they stated that C oronary artery bypass grafting (CABG) surgery using cardiopulmonary bypass (CPB) can be associated with neurological, renal, and pulmonary morbidity, as well as with inflammatory and hemostatic complications. Coronary artery bypass grafting without the use of CPB, off-pump coronary artery bypass (OPCAB) surgery, became increasingly popular in the early 1990s with the development of new techniques for coronary exposure and stabilization of the myocardium. The main advantages of OPCAB surgery over the CPB technique include less traumatic surgical intervention, shortened hospital or intensive care unit (ICU) stay, and reduced patient recovery time. It was expected that more than 50% of all coronary revascularization To characterize hemostatic differences imposed by 2 common cardiac surgeries, the authors studied patients undergoing coronary artery revascularization by offpump (n = 13) or cardiopulmonary bypass on-pump (n = 26) technique. Blood samples collected to 4 days postsurgery were evaluated by flow cytometry and enzymelinked immunosorbent assay. A significant inflammatory response occurred in both the groups after surgery shown by increased interleukin cytokines and C-reactive protein; however, levels peaked lower and hours later in the off-pump group. Platelets (P-selectin; platelet-leukocyte complexes) and leukocytes (CD11b) were activated only in on-pump patients. Thrombin generation was enhanced in both groups after surgery. Only in the on-pump patients, the thrombin-antithrombin complex, prothrombin fragment 1.2, and thrombomodulin (vascular integrity) decreased intraoperatively. Tissue plasminogen activator and plasminogen activator inhibitor-1 were greater in the on-pump patients. Off-pump surgery may place patients at higher risk of postoperative hypercoagulability because of normal platelet function, intraoperative thrombin generation, less fibrinolytic activity, and lack of vascular protection. Keywords: cardiopulmonary bypass; off-pump; inflammation; platelets; thrombin generation a reduced number of grafts and completeness of revascularization and increased repeat revascularization are associated with OPCAB. 1, 3, 4 Other studies report on pulmonary embolism 5 and early cognitive decline 6 after OPCAB.
It was assumed that elimination of the heartlung machine would prevent the inflammatory and hemostatic problems associated with on-pump surgery. A number of studies have suggested reduced complement, inflammatory, and hemostatic activation. [7] [8] [9] [10] However, other studies have suggested that OPCAB surgery may cause a greater disruption of the inflammatory and hemostatic systems. [11] [12] [13] [14] Thus, not only does the debate on the choice of on-pump versus off-pump CABG continue, 15 but also the inflammatory and hemostatic mechanisms associated with each surgery remain unsettled. To further characterize and better understand the differences imposed by the two surgical techniques, we evaluated acute phase reactants, cellular elements, and hemostatic activation using new and different biomarkers.
Materials and Methods

Patient Selection
This prospective study was approved by the Loyola University Medical Center Institutional Review Board, and all patients gave written informed consent before surgery. Thirty-nine patients, adults (>18 years) undergoing their first cardiac surgery, underwent either CPB (n = 26) or OPCAB (n = 13) coronary artery revascularization. All incoming patients were included in the study. Only the patients having a redo surgical procedure or a combination surgery were excluded from participation. The patients were not randomized but were assigned to treatment group based on an optimal surgical approach and a standard of care for the given clinical condition.
Operative Procedures
Cardiopulmonary bypass was carried out using the standard techniques with cardioplegic arrest. Heparin was administered to a target-activated clotting time (ACT) of 480 seconds (∼3 mg/kg heparin). All OPCAB patients underwent median sternotomy and epicardial stabilization with the Octopus Tissue Stabilizer (Medtronic, Minneapolis, Minnesota). The OPCAB group had partial heparinization with a target-ACT of 350 seconds (∼2 mg/kg heparin). Both groups were given full protamine neutralization, and aspirin was initiated on postoperative day 1 (POD 1).
Sample Collection
Special care was taken for proper blood collection and handling. Blood samples were collected in 3.2% sodium citrate from patients at 8 time points: after sternotomy but prior to heparin administration (baseline), 30 minutes after conduit harvest, immediately after completion of the last proximal anastomosis (end of anastomosis), and postoperatively at 2, 10, 20, 48, and 96 hours (or at discharge if discharge was earlier than 96 hours after operation).
Flow Cytometry
Aliquots of whole blood were fixed in 1% parrmaldehyde at 4°C. After 30 minutes, fixed blood samples were centrifuged at 350 g for 10 minutes. The supernatant was removed, and the cell pellets were resuspended in 800 μL of calcium-free Tyrode's buffer (pH 7.4 ± 0.1). The aliquots of resuspended cells were labeled with antibodies (isotypes) to determine platelet and neutrophil activation. Platelet activation was measured in terms of platelet P-selectin (CD62P) expression and formation of plateletneutrophil aggregates. Neutrophil activation was measured in terms of Mac-1 receptor (CD11b) expression. CD16b FITC (clone ICRF 44 to identify neutrophils) was obtained from Beckman-Coulter (Miami, Florida), and CD11b PE (clone 1D3 to identify activated neutrophils) was obtained from Pharmingen (San Diego, California). CD61FITC (clone RUU-PL 7F12 to identify platelets) and CD62PE (clone AC1.2 to identify activated platelets) were obtained from Becton-Dickinson (San Jose, California). The samples were analyzed on a Coulter EPICS XL flow cytometer (Beckman-Coulter, Hialeah, Florida). Data were analyzed using the WinMDI 2.8 program (Joseph Trotter, http://facs.scripps.edu/ facsindex .html).
Inflammatory and Hemostatic Markers
Following sample processing for the flow cytometric analysis, the remaining citrated whole blood was centrifuged (1250 g for 10 minutes) within 1 hour of collection to obtain platelet-poor plasma. The plasma was stored at -70°C until analyzed. Interleukin (IL)-8 and IL-6 were measured with OptEIA human interleukin sets (Pharmingen). High-sensitivity C-reactive protein (hsCRP) was measured with Imuclone ELISA (enzyme-linked immunosorbent assay) kits (American Diagnostica, Stamford, Connecticut) and thrombomodulin was measured with Imubind ELISA kits (American Diagnostica). Tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) were measured using Asserachrom ELISA kits (Diagnostica Stago, Asnieres, France). Thrombin-antithrombin complex (TAT) and prothrombin fragment F1.2 (F1.2) were measured using Enzygnost Micro kits (Dade Behring, Marburg, Germany). The kits to measure soluble intercellular adhesion molecule-1 (ICAM-1) were obtained from BioSource International (Camarillo, California). The assays were performed according to manufacturers' directions, with appropriate controls and standards. The normal reference ranges for each analyte were established by the lab (20 male and 20 female patients who were apparently healthy). The upper limit of normal was calculated as the mean + 3 standard deviations of this normal population.
Clinical Data
Clinical data, including demographics, complete blood count, hospital course, and occurrence of adverse events (return to operating room , multisystem organ failure, shock, thrombosis, death), were obtained from medical charts. Postoperative adverse events were recorded for a 30-day follow-up period.
Statistical Analysis
Statistical analyses were carried out using Sigma Stat version 2.01 (SpSS, Chicago, Illinois). The 1-way and 2-way analyses of variance (ANOVA), with and without repeated measures, were computed to determine the significant differences between groups when appropriate. Tukey's post hoc and Student's t test were used to determine the differences between 2 means. Z-test was used to compare percentages. P values ≤ .05 were considered statistically significant.
Results
The demographics descibing the CPB-CABG and OPCAB patient groups are provided in Table 1 . Only the frequencies of chronic obstructive pulmonary disease and hypertension were different between the 2 groups. The frequencies of coronary artery disease, myocardial infarction, cerebrovascular attack, peripheral vascular disease, congestive heart failure, and angina were equally distributed between the 2 groups. At baseline, there was no significant difference between the 2 groups in the type or frequency of medications that the patients were using. In particular, steroids and aspirin that could affect cytokine levels were used in the same frequency in the 2 patient groups.
On average, there were more grafts per patient performed in the CPB-CABG than in the OPCAB group, resulting in a longer skin-to-skin time in the CPB group (Table 2 ). There were no adverse events reported perioperatively or during the 30-day followup. Only the incidences of chronic obstructive pulmonary disease and hypertension were significantly different between the groups.
Hemodynamic data that were recorded throughout the surgery and up to 12-hours postsurgery showed no differences between the groups. Parameters that were measured included heart rate, mean arterial pressure, central venous pressure, pulmonary artery diastolic pressure, cardiac output index, and mixed venous oxygen saturation.
Interleukin-8, IL-6, and CRP were measured as indices of inflammation ( Figure 1 ). Interleukin-8 was significantly increased relative to baseline and above the upper limit of normal from the time of the last anastomosis until 24 hours post surgery in both groups. Although IL-8 peaked earlier and higher in the CPB-CABG patients (2 hours postsurgery compared with 8-12 hours postsurgery in the OPCAB patients), statistical differences in IL-8 levels Inflammatory and Hemostatic Activation OPCAB / Untch et al 143 between the groups were not observed. Interleukin-6 was increased relative to baseline and well above the upper limit of normal in both groups at 2 to 48 hours postsurgery. As with IL-8, peak levels of IL-6 occurred later in the OPCAB patients (24 hours postsurgery) compared with the CPB-CABG patients (8-12 hours). C-reactive protein was significantly increased relative to baseline and well above the upper limit of normal, beginning 8 to12 hours postsurgery and remained elevated 96 hours postsurgery in both the groups. At each time point, CRP was significantly higher in the CPB-CABG patients than in patients undergoing OPCAB.
White blood cell (WBC) count increased in both groups following surgery. Upon leaving the operating room (POD 0), the WBC count was significantly higher in patients undergoing OPCAB than in patients undergoing CPB-CABG (15.78 ± 1.32 vs 12.44 ± 0.67 × 10 3 /μL; p < .05). Hemodilution could account for the lower count in the CPB group. Neutrophil activation was measured by Mac-1 receptor upregulation (CD11b expression in terms of mean fluorescence intensity). Neutrophil CD11b expression was significantly greater in the CPB-CABG group at 30 minutes intraoperatively through 2-hours postsurgery but returned to baseline levels by 24 hours (Figure 2 ). No increase in CD11b expression was observed in the OPCAB patients.
Although both OPCAB and CPB-CABG patients exhibited a postoperative decrease in platelet count, a significant difference between the groups was only evident immediately after surgery (POD 0; 174.1 ± 17.5 × 10 3 /μL OPCAB vs 126.1 ± 10.1 × 10 3 /μL CPB-CABG; Figure 3 ). Hemodilution and consumption likely account for the lower count in the CPB group. Platelet activation, as measured by the expression of P-selectin (CD62), was significantly elevated from baseline (4.0% ± 0.2%) in the CPB-CABG group at 30 minutes (6.3% ± 0.8%), at the end of anastomosis (6.0 ± 0.7%), and 2-hours after surgery (7.0 ± 2.4%). This occurred at a later time and was not parallel to the platelet count decrease. Similarly, the amount of platelet-neutrophil aggregates was increased from baseline (6.2% ± 0.3%) at 30 minutes (10.1% ± 1.5%), at the end of anastomosis (11.1% ± 2.2%), and 2-hours after surgery (8.8% ± 3.1%) in the CPB-CABG group (p < 0.005 vs baseline). There was no change, relative to the baseline in the amount of platelet-neutrophil complexes observed in patients who underwent OPCAB. Using the PlateletWorks assay (Helena Laboratories, Beaumont, Texas) platelet functionality in response to ADP was determined in a subset of patients at baseline and at the end of anastomosis in 16 patients undergoing CPB-CABG and 9 patients undergoing OPCAB (data not shown). Baseline ADP-induced platelet activation was comparable in both groups (73.0 ± 8.2% OPCAB vs 77.1 ± 5.7% CPB-CABG). Although the extent of platelet aggregation in the OPCAB patients was increased slightly at the end of anastomosis (79.1 ± 5.7%), a significantly stronger aggregation response was observed in the CPB-CABG patients (89.9 ± 2.8%; p < 0.005 vs OPCAB), indicating more intraoperative platelet activation in the CPB-CABG patients.
Thrombin generation was elevated in both CPB and OPCAB groups relative to the upper limit of normal of TAT (8.7 ng/mL) and F1.2 (2 nM) throughout the study period (Figure 4) . No large differences between the groups were observed. However, there was a reduction in TAT at 30 minutes and at the end of anastomosis in the CPB-CABG group. In addition, a marked increase in both TAT and F1.2 was observed in the CPB-CABG patients 2 hours after surgery.
The effect of surgery on the fibrinolytic system was assessed in terms of circulating tPA and PAI-1 ( Figure 5 ). Although tPA was increased significantly relative to baseline and above the upper limit of normal (10 ng/mL) in both groups at 2 hours postsurgery, there was no difference between the groups. Plasminogen activator inhibitor-1 was significantly elevated above the upper limit of normal (48 ng/mL) 2 hours postsurgery through 24 hours postsurgery in both groups. Peak levels of PAI-1 were approximately 2-fold higher in the CPB-CABG group (195 ± 17 ng/mL) than in the OPCAB group (104 ± 24 ng/mL).
Endothelial damage or activation was measured in terms of soluble ICAM-1 and soluble thrombomodulin ( Figure 6 ). In both surgical groups, thrombomodulin was higher than the upper limit of normal (<2 ng/mL thrombomodulin), but ICAM-1 was within the normal range (<30 ng/mL ICAM-1). Intercellular adhesion molecule-1 was not altered by the surgical procedure in either group. In the OPCAB patients, thrombomodulin was not altered by the surgical procedure, but in the CPB-CABG patients, thrombomodulin levels were significantly reduced at 30 minutes and at the end of anastomosis.
Discussion
This study demonstrates inflammatory and hemostatic activation in patients undergoing CABG with either CPB or OPCAB, as summarized in Table 3 . Cytokine (IL-8, IL-6) and acute-phase reactant (CRP, PAI-1) upregulation in both surgical groups showed a sustained inflammatory response resulting from the operative trauma and not dependent on CPB. However, differences between the 2 surgical techniques were observed. With CPB, the IL-6, IL-8, and CRP peak responses occurred earlier and were higher; in addition, neutrophil activation and neutrophil-platelet aggregate formation were shown. An analysis was performed to determine whether the duration of operation affected the extent of inflammatory activation. In patients undergoing CABG with CPB, longer surgical times were positively correlated with the increased levels of IL-6, IL-8, IL-10, thrombomodulin, ICAM-1, and PAI-1 in the perioperative and immediate postoperative periods (end of anastomoses and 2 hours postsurgery time points). By 8 hours postsurgery, there was no correlation between cytokine levels and operative duration. In the OPCAB patients, the extent of inflammatory activation at any of the time points measured was not predictable based on operative time. Our observations are consistent with the findings of others that the inflammatory response, although significant in both CPB and OPCAB, is more pervasive in patients exposed to CPB. [16] [17] Mechanical trauma, altered shear stresses, foreign surfaces, and hypothermia promote platelet activation in cardiopulmonary bypass, but less is known about the effects of OPCAB on platelets. In our study, CPB was associated with platelet activation, platelet-leukocyte aggregate formation, and hyperactivity of platelets, whereas OPCAB was not associated with these platelet responses. These data suggest that platelets are more normal (less spent, not preactivated) in the OPCAB patients.
Others have shown that von Willebrand factor (vWF) release occurs due to the stress of surgery and is the same with CPB and OPCAB, but that vWF activity is lower after CPB. 18 The finding that vWF activity is higher after OPCAB, combined with our observation that platelets are more active after OPCAB, enhances the possibility of a post-OPCAB hypercoagulable state with the risk of postoperative platelet-mediated thrombosis. The authors of the vWF study were able to show that increased postoperative D-dimer and vWF levels correlated with early postoperative cognitive decline in the OPCAB patients. 6, 18 A hypercoagulable state as measured by an increase in thrombin generation was observed in both surgical groups. Yet in the CPB group, it was interesting to note that thrombin generation (TAT) was suppressed during surgery, assumed to be due to the high heparin dosing. Some effects of hemodilution cannot be ruled out but seem unlikely because no intraoperative decrease was observed with F1.2. There was also a surge of coagulation activation immediately after surgery in the CPB group. This is assumed to be associated with a reperfusion injury that accompanies the release of the cross-clamp with the discontinuation and reversal of heparin as suggested by Raivio et al. 19 Although the fibrinolytic system was activated in both surgical groups, there was more tPA release intraoperatively with CPB than with OPCAB, suggesting a heightened profibrinolytic state. The lesser upregulation of PAI-1 with OPCAB is likely related to the reduced inflammatory response.
Alterations of the vascular endothelium due to surgical techniques were not shown as no changes in soluble ICAM-1 or soluble thrombomodulin were detected postoperatively. However, the data present some interesting insights. The consistently elevated thrombomodulin level is indicative of the underlying vascular damage in this patient population. The decrease in thrombomodulin during CPB Inflammatory and Hemostatic Activation OPCAB / Untch et al 147 NOTE: CPB = cardiopulmonary bypass; CPB-CABG = on-pump cardiopulmonary bypass-coronary artery bypass grafting; OPCAB = off-pump coronary artery bypass; IL = Interleukin; CRP, C-reactive protein; WBC = white blood cells; F 1.2 = prothrombin fragment 1.2; tPA = tissue plasminogen activator; PAI-1 = plasminogen activator-1; ICAM-1 = intercellular adhesion molecule-1; TAT = thrombin-antithrombin complex.
(more significant than that of ICAM-1, which probably reflects the hemodilution effect) may be related to the presence of heparin. This raises the issue of a potential advantage of the high dose of heparin used in CPB in maintaining a quiescent vascular endothelium.
Given the wide range of protocols that are said to be used for OPCAB, one wonders if these modifications from what was routine with CPB were implemented due to unfounded worry or due to an actual reason, such as thrombosis, that went undocumented. We propose that following OPCAB, the more normal platelet function, in the background of thrombin generation and lesser fibrinolytic upregulation, may put OPCAB patients at a higher risk of graft closure than CPB patients. Furthermore, as the use of heparin may be protective, minimizing anticoagulation may not be optimal in surgical patients.
